Cytek Biosciences, Inc.

NASDAQ:CTKB

Medical - Devices

Healthcare
$5.92 -2.64%

-$0.11 today

Market cap
$774.24M
Beta
1.19
P/E (TTM)
-6.7
EPS (TTM)
-$0.57
52W Low $2.90High $6.18

Volume 1.05M

Average 0.88M

CTKB Inventory

Cash effect of the change in inventory; building inventory consumes cash.

Cytek Biosciences, Inc.NASDAQ: CTKB

Inventory · Q1 FY2026 · quarter ended Mar 2026

Inventory growth accelerates

Q1 FY2026 inventory of $1.63M (cash outflow) rose 8.3% year over year, ahead of the -163.3% change in trailing-twelve-month inventory. Over 3 fiscal years it compounded at -33.3% a year.

Context

  • Inventory amounted to 2.6% of revenue in FY2025, down 4.8 pp from a year earlier.
  • Inventory increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +8.3% holds above the trailing-twelve-month pace of -163.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.63M-179.3% QoQ
Last fiscal yearDec 2025
-$5.24M-135.5% YoY
LTMMar 2026
-$5.37M-163.3% YoY
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.3%——
1 year-135.5%——
3-year CAGR-33.3%——
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the cash flow

Latest · FY2025
(5.24M) USD
Year-over-year change
-135.5%

Inventory vs competitors

How CTKB compares with its peers on the latest reported figures

  • CTKB's LTM Mar 2026 inventory of $5.37M is the 5th largest of the 6 companies compared; the peer median is $2.78M.
  • Its year-over-year change of -163.3% is the 5th highest of 6, against a peer median of +64.2%.
  • Inventory amounts to 2.6% of revenue for CTKB, versus a peer median of 2.5%.
CTKB Competitors Peer median
Inventory for CTKB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAgilent Technologies, Inc.LTM Jul 2026$135M +154.7%—1.8%
BRKRBruker CorporationLTM Jun 2026$70.9M -393.0%—2.0%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$65.2M +64.2%—2.5%
TXG10x Genomics, Inc.LTM Jun 2026$18.57M -9.1%—3.0%
CTKBCytek Biosciences, Inc.LTM Mar 2026$5.37M -163.3%-33.3%2.6%
LABStandard BioTools Inc.LTM Mar 2026$2.78M +137.7%+10.8%3.2%
Peer median (excluding CTKB) $2.78M+64.2%+10.8%2.5%

Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income3.03M2.48M(12.15M)(6.02M)(66.54M)
Depreciation & Amortization1.24M5.66M9.23M10.49M11.98M
Deferred Income Tax000(2.89M)33.56M
Stock-Based Compensation6.59M16.6M22.05M26.85M24.59M
Change in Working Capital(8.65M)(39.93M)(10.51M)7.71M(4.79M)
Accounts Receivables(12.37M)(19.74M)(7.33M)(5.43M)368K
Inventory(7.07M)(17.65M)4.29M14.76M(5.24M)
Accounts Payables(256K)1.86M(1.78M)2.58M448K
Other Working Capital11.05M(4.39M)(5.68M)(4.2M)(366K)
Other Non-Cash Items2.42M2.96M(3.34M)(10.77M)(3.47M)
Operating Cash Flow4.63M(12.23M)5.28M25.38M(4.69M)
Capital Expenditures(4.36M)(9.87M)(4.83M)(3.53M)(4.08M)
Acquisitions (Net)(16.63M)0(45.13M)(471K)252K
Purchases of Investments0(46.04M)(175.94M)(274.06M)(278.16M)
Sales of Investments00132M195M292.21M
Other Investing Activities0(120K)(179K)84K(107K)
Investing Cash Flow(20.99M)(55.91M)(93.89M)(82.97M)10.12M
Debt Repayment(2.77M)2.93M(565K)3.62M837K
Common Stock Issued215.69M2.79M001.47M
Common Stock Repurchased00(44.15M)(21.61M)(15.07M)
Dividends Paid00000
Other Financing Activities642K(209K)2.9M2.17M(669K)
Financing Cash Flow213.56M5.51M(41.81M)(15.82M)(13.43M)
Effect of Forex Changes1.3M(2.49M)(1.45M)4.53M109K
Net Change in Cash198.5M(65.12M)(131.87M)(68.89M)(7.89M)
Free Cash Flow266K(22.1M)454K21.85M(8.77M)

Cytek Biosciences, Inc.

NASDAQ:CTKB

Intrinsic Alpha fair value

Locked

Current Price

$5.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.